Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to the new strategy that aims to awaken the immune system to fight cancer cells, there has been a change in the clinical course in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Our study aimed to evaluate the therapeutic efficacy of nivolumab monotherapy in the treatment of patients with advanced stage IIIB/IV non-small cell lung cancer beyond the second line. The results showed a progression-free survival of 7.35 months and an improvement in the quality of life of patients compared to other treatments. In addition, no type 3 and type 4 adverse reactions were detected in patients treated with Nivolumab. We hope that these results, already promising, will lead to an increase in overall survival in the future.

Fabio Venturella, Giulia Cancellieri, Marco Giammanco, Anna Maria Almerico, Igor Daniele Aleo, Anastasia Valentina Liga, et al. (2023). Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab. JOURNAL OF BIOLOGICAL RESEARCH, 96, 32-35 [10.4081/jbr.2023.11027].

Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab

Fabio Venturella;Giulia Cancellieri;Marco Giammanco;Anna Maria Almerico;Igor Daniele Aleo;Francesca Mortillaro;
2023-01-01

Abstract

Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to the new strategy that aims to awaken the immune system to fight cancer cells, there has been a change in the clinical course in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Our study aimed to evaluate the therapeutic efficacy of nivolumab monotherapy in the treatment of patients with advanced stage IIIB/IV non-small cell lung cancer beyond the second line. The results showed a progression-free survival of 7.35 months and an improvement in the quality of life of patients compared to other treatments. In addition, no type 3 and type 4 adverse reactions were detected in patients treated with Nivolumab. We hope that these results, already promising, will lead to an increase in overall survival in the future.
2023
Fabio Venturella, Giulia Cancellieri, Marco Giammanco, Anna Maria Almerico, Igor Daniele Aleo, Anastasia Valentina Liga, et al. (2023). Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab. JOURNAL OF BIOLOGICAL RESEARCH, 96, 32-35 [10.4081/jbr.2023.11027].
File in questo prodotto:
File Dimensione Formato  
JBiolRes2023_96_1_11027.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 1.09 MB
Formato Adobe PDF
1.09 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/599695
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact